Drugs / INCB059872
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03514407 | Jun 2018 → Jun 2020 | Ewing sarcoma | Incyte Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03132324 | Apr 2017 → Oct 2018 | sickle cell disease | Incyte Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02959437 | Feb 2017 → Feb 2019 | metastatic malignant neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02712905 | May 2016 → Apr 2022 | hematopoietic and lymphoid system neoplasm | Incyte Corporation | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB059872 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02712905 ↗ |
| Known as | Incb 59872 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095243 ↗ |
| Action | Inhibit | “lysine-specific demethylase 1A (LSD1) inhibitor INCB059872” NCT02959437 ↗ |
| Modality | Small molecule | — CHEMBL5095243 ↗ |
| Route | Oral | “INCB059872 tablets to be administered by mouth.” NCT02712905 ↗ |